Vaxcyte (PCVX) Net Cash Flow (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Net Cash Flow of $87.5 million for Q1 2026, up 307.47% year-over-year from $21.5 million in Q1 2025, and up 181.59% quarter-over-quarter from -$107.3 million in Q4 2025.
Vaxcyte (PCVX) Net Cash Flow (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Net Cash Flow for 8 consecutive years, with $87.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 307.47% year-over-year to $87.5 million; the TTM figure through Mar 2026 stood at -$86.5 million (up 66.74% YoY), while the FY2025 annual figure was -$216.2 million, down 2109.6% from the prior year.
- Net Cash Flow improved to $87.5 million in Q1 2026 per PCVX's latest filing, from -$107.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $555.5 million in Q4 2022 and bottomed at -$663.7 million in Q4 2024.
- Historically, Net Cash Flow has averaged $11.6 million across 5 years, with a median of $13.3 million in 2023.
- Annual changes were most pronounced in 2023 — Net Cash Flow plunged 441.57% — and 2024, when it soared 3945.4%.
- Vaxcyte's Net Cash Flow stood at $555.5 million in 2022, then tumbled by 125.2% to -$140.0 million in 2023, then slumped by 374.04% to -$663.7 million in 2024, then soared by 83.83% to -$107.3 million in 2025, then jumped by 181.59% to $87.5 million in 2026.
- Business Quant data shows PCVX's Net Cash Flow at $87.5 million in Q1 2026, -$107.3 million in Q4 2025, and -$25.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | -79.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.05 Mn |
| Jun 30, 2026 | -79.05 Mn |
| Mar 31, 2026 | 87.55 Mn |
| Mar 31, 2026 | 87.55 Mn |
| Dec 31, 2025 | -107.30 Mn |
| Dec 31, 2025 | -107.30 Mn |
| Sep 30, 2025 | -25.81 Mn |
| Sep 30, 2025 | -25.81 Mn |
| Jun 30, 2025 | -40.91 Mn |
| Jun 30, 2025 | -40.91 Mn |
| Mar 31, 2025 | -42.20 Mn |
| Mar 31, 2025 | -42.20 Mn |
| Dec 31, 2024 | -663.66 Mn |
| Dec 31, 2024 | -663.66 Mn |
| Sep 30, 2024 | 537.31 Mn |
| Sep 30, 2024 | 537.31 Mn |
| Jun 30, 2024 | -91.43 Mn |
| Jun 30, 2024 | -91.43 Mn |
| Mar 31, 2024 | 208.00 Mn |
| Mar 31, 2024 | 208.00 Mn |